Literature DB >> 17599032

Chronic fatigue syndrome after Q fever.

Dragan Ledina1, Nikola Bradarić, Ivo Milas, Ivo Ivić, Nada Brncić, Nikica Kuzmicić.   

Abstract

BACKGROUND: Q fever is a common and acute but rare chronic zoonosis caused by Coxiella burnetii. Its acute form manifests as atypical pneumonia, flu-like syndrome, or hepatitis. Some authors observed symptoms of chronic fatigue in a small number of patients after the acute phase of Q fever; in many cases serological assay confirmed the activity of Coxiella burnetii infection. The effect of antibiotic therapy on post-Q-fever fatigue syndrome has not been studied in south-east Europe thus far. CASE REPORTS: Three patients are presented with post-Q-fever fatigue syndrome. All fulfilled the CDC criteria for chronic fatigue syndrome. IgA antibodies to phase I of the growth cycle of Coxiella burnetii were positive in two patients and negative in one. Two patients were treated with doxycycline for two weeks in the acute phase of illness and one with a combination of erythromycin and gentamycin. After 4-12 months they developed post-Q-fever fatigue syndrome and were treated with intracellular active antibiotics (fluoroquinolones and tetracycline) for 3-12 months. Efficacy of the treatment was observed in two patients, but in one patient the results were not encouraging.
CONCLUSIONS: These results suggest the possibility of the involvement of Coxiella burnetii infection in the evolution of chronic fatigue syndrome. This is the first report on post-Q-fever fatigue syndrome in Mediterranean countries. Evidence of IgA antibodies to phase I of the growth cycle of Coxiella burnetii is not a prerequisite for establishing a diagnosis of CFS. The recommendation of antibiotic treatment in post-Q-fever fatigue syndrome requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17599032

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  7 in total

Review 1.  From Q Fever to Coxiella burnetii Infection: a Paradigm Change.

Authors:  Carole Eldin; Cléa Mélenotte; Oleg Mediannikov; Eric Ghigo; Matthieu Million; Sophie Edouard; Jean-Louis Mege; Max Maurin; Didier Raoult
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

2.  Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26.

Authors:  Mary A Fletcher; Xiao R Zeng; Kevin Maher; Silvina Levis; Barry Hurwitz; Michael Antoni; Gordon Broderick; Nancy G Klimas
Journal:  PLoS One       Date:  2010-05-25       Impact factor: 3.240

3.  Plasma neuropeptide Y: a biomarker for symptom severity in chronic fatigue syndrome.

Authors:  Mary A Fletcher; Martin Rosenthal; Michael Antoni; Gail Ironson; Xiao R Zeng; Zachary Barnes; Jeanna M Harvey; Barry Hurwitz; Silvina Levis; Gordon Broderick; Nancy G Klimas
Journal:  Behav Brain Funct       Date:  2010-12-29       Impact factor: 3.759

Review 4.  Fatigue following Acute Q-Fever: A Systematic Literature Review.

Authors:  Gabriella Morroy; Stephan P Keijmel; Corine E Delsing; Gijs Bleijenberg; Miranda Langendam; Aura Timen; Chantal P Bleeker-Rovers
Journal:  PLoS One       Date:  2016-05-25       Impact factor: 3.240

5.  From good health to illness with post-infectious fatigue syndrome: a qualitative study of adults' experiences of the illness trajectory.

Authors:  Eva Stormorken; Leonard A Jason; Marit Kirkevold
Journal:  BMC Fam Pract       Date:  2017-03-27       Impact factor: 2.497

6.  Plasma cytokines in women with chronic fatigue syndrome.

Authors:  Mary Ann Fletcher; Xiao Rong Zeng; Zachary Barnes; Silvina Levis; Nancy G Klimas
Journal:  J Transl Med       Date:  2009-11-12       Impact factor: 5.531

7.  The Qure study: Q fever fatigue syndrome--response to treatment; a randomized placebo-controlled trial.

Authors:  Stephan P Keijmel; Corine E Delsing; Tom Sprong; Gijs Bleijenberg; Jos W M van der Meer; Hans Knoop; Chantal P Bleeker-Rovers
Journal:  BMC Infect Dis       Date:  2013-03-27       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.